Related Experiment Video

Updated: May 8, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Metrics other than potency reveal systematic variation in responses to cancer drugs

Mohammad Fallahi-Sichani1, Saman Honarnejad, Laura M Heiser

  • 1Harvard Medical School Library of Integrated Network-based Cellular Signatures Center, Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA.

Nature Chemical Biology
|September 10, 2013
PubMed

Insights

Beyond drug potency (IC50), multiparametric analysis reveals other crucial factors in anticancer drug response. Understanding dose-response curve parameters and cell variability is key for effective cancer treatment strategies.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Cancer Therapeutics

Background:

  • Anticancer drug efficacy is often assessed solely by potency (IC50).
  • This focus overlooks other critical pharmacological parameters influencing drug response.
  • Cellular heterogeneity can complicate drug response assessments.

Purpose of the Study:

  • To investigate multiparametric dose-response characteristics of anticancer drugs.
  • To explore the relationship between drug response parameters and cell characteristics.
  • To identify factors beyond potency affecting drug efficacy and resistance.

Main Methods:

  • Large-scale cellular response analysis using a multiparametric approach.
  • Evaluation of dose-response curve slope, area under the curve (AUC), and maximum effect (Emax).
  • Single-cell analysis to investigate cell-to-cell variability in target inhibition.

Main Results:

  • Drug response parameters vary systematically with cell line and drug class.
  • For cell-cycle inhibitors, Emax often correlates with proliferation rate.
  • Akt/PI3K/mTOR pathway inhibitors exhibit shallow dose-response curves linked to target inhibition variability.

Conclusions:

  • Potency (IC50) alone is insufficient for comprehensive drug response analysis.
  • Multiparametric evaluation, including Emax and curve shape, provides deeper insights.
  • Cell-to-cell variability in target inhibition influences drug response, especially at higher concentrations.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.